Get the Stockscreener App
18.93
1.50%
0.28
Rigel Pharmaceuticals stock is traded at $18.93, with a volume of 97,440.
It is up +1.50% in the last 24 hours and down -7.16% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$18.65
Open:
$18.84
24h Volume:
97,440
Relative Volume:
0.47
Market Cap:
$378.72M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-135.21
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+0.91%
1M Performance:
-7.16%
6M Performance:
+8.92%
1Y Performance:
+144.89%
1-Day Range:
$18.65
$19.18
1-Week Range:
$18.24
$19.79
52-Week Range:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
18.93 | 378.72M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com
Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World
Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com
Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq
Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance
Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider
Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? - sharewise
Rigel to Present at the Jefferies Global Healthcare Conference | RIGL Stock News - GuruFocus
(RIGL) Proactive Strategies - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: stock performance and pipeline potential By Investing.com - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: stock performance and pipeline potential - Investing.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Grows Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals Approves Equity Plan Amendment - TipRanks
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress | RIGL Stock News - GuruFocus
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress - PR Newswire
Jane Street Group LLC Has $1.05 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
17,123 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Acquired by Dimensional Fund Advisors LP - Defense World
(RIGL) Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why - simplywall.st
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now? - Yahoo Finance
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet - MSN
Upgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Forecasts - Yahoo Finance
Wells Fargo & Company MN Buys 2,648 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Cantor Fitzgerald Brokers Reduce Earnings Estimates for RIGL - Defense World
B. Riley Expects Reduced Earnings for Rigel Pharmaceuticals - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Earnings Estimates Rising for Rigel (RIGL): Will It Gain? - Yahoo Finance
MetLife Investment Management LLC Acquires 2,014 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
HC Wainwright Issues Positive Outlook for RIGL Earnings - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of “Hold” by Analysts - Defense World
Rigel Pharmaceuticals Reports Strong Growth and Strategic Advances - TipRanks
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) Price Target Raised by Cantor Fitzg - GuruFocus
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rigel Pharmaceuticals Stock (RIGL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):